therefore does not require a heart-lung bypass machine. In addition to improving blood flow through the heart, the procedure may also relieve symptoms such as fatigue and shortness of breath that often affect patients with significant MR. After treatment, patients generally recover quickly. The MitraClip(R) device may improve quality of life and may help MR patients avoid or delay surgery, having preserved surgical options (valve repair or replacement) should surgery become necessary.
About Evalve, Inc.
Founded in 1999, Evalve, Inc., headquartered in Menlo Park, Calif., has developed a proprietary system which enables percutaneous repair of cardiac valves. The company's initial products are intended to reduce the risks, trauma and costs associated with current open, arrested heart surgical options. For more information about Evalve, Inc., and for an animated explanation of the procedure using the MitraClip(R) device, visit www.evalveinc.com. Evalve is the first portfolio company from the medical device company incubator, The Foundry (www.thefoundry.com).
The MitraClip(R) system is currently undergoing clinical evaluation in the United States and Canada.
MitraClip(R) and Evalve(R) are registered trademarks of Evalve, Inc.
Media Contact:
Amy Hytowitz
Edelman
1-323-202-1028
Amy.Hytowitz@edelman.com
'/>"/>SOURCE Evalve, Inc. Copyright©2009 PR Newswire. All rights reserved | |
Page: 1 2 3 Related medicine news :1.
Integrated Medical Systems Receives $1.1 Million From the U.S. Department of Defense for Critical Enhancements of the Worlds First Suitcase Intensive Care Unit2.
Mount Sinai first with new technique to prevent a major cause for heart-related stroke3.
School Kids, Parents Should Get Flu Vaccines First4.
Tevas Patient First Initiative Highlights Struggle Against High Health Care Costs, Reminds Lawmakers of Reform Goals5.
49 Companies Submit Products for First Spine Technology Awards; Entries Now Closed6.
MN Community Measurement Launches First-Of-Its-Kind Quality Measure For Depression Care7.
National Practice Transition Network Attracting National Attention as the Country's First Membership-Based, Commission-Free Dental Practice Transition Company 8.
Cyberonics Reports Strong Fiscal 2010 First Quarter Results9.
A UK Cosmetic Surgery First: An Eyelash Transplant Procedure10.
Mylans Matrix Receives First and Only Tentative FDA Approval Under PEPFAR for Generic Version of Atripla(R) HIV Treatment11.
CA$H-First(SM) LTCi Provides First-Day Cash Benefits at Affordable Rates